Role of Angiotensin II in coronary artery lesion of Kawasaki disease

Research Project

Project/Area Number	20790750
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Single-year Grants
Research Field	Pediatrics
Research Institution	Tokai University
Principal Investigator	SUGANUMA Eisuke Tokai University, 医学部, 助教 (60408010)
Project Period (FY)	2008 – 2010
Project Status	Completed (Fiscal Year 2010)
Budget Amount *help	¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000) Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2008: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords	小児循環器 / 川崎病 / アンギオテシン受容体拮抗薬 / 川崎病モデルマウス / マクロファージ / アンギオテンシン受容体拮抗薬 / アンギオテンシン / カテプシン
Research Abstract	Extracellular matrix(ECD) such as INF-γ,TNF-α,IL-6,MMPs are thought to be involved in coronary artery lesions (CAL) in patients with Kawasaki disease (KD). The mechanisms underlying effects of ARB in CAL are not known. We discussed whether ARB could prevent Lactobacillus casei cell wall extract (LCWE)-induced coronary arteritis in murine model of KD. Inflammations in response to LCWE, are suppressed by ARB treatment. More interestingly, MMP-2, MMP-9, IL-6 mRNA expression at local coronary artery significantly decreased in mice treated with ARB compared with mice post-LCWE injection. Thus, this result suggests that ARB is expected to be a new therapeutic agent for preventing CAL in patient with Kawasaki disease.